| Literature DB >> 27402233 |
Keren Shahar1, Wisam Darawsha1, Sergey Yalonetsky1, Jonathan Lessick1, Michael Kapeliovich1, Robert Dragu1, Diab Mutlak1, Shimon Reisner1, Yoram Agmon1, Doron Aronson2.
Abstract
BACKGROUND: The clinical importance of right ventricular (RV) function in acute myocardial infarction is well recognized, but the impact of concomitant pulmonary hypertension (PH) has not been studied. METHODS ANDEntities:
Keywords: heart failure; myocardial infarction; pulmonary hypertension; right ventricle infarction
Mesh:
Year: 2016 PMID: 27402233 PMCID: PMC5015396 DOI: 10.1161/JAHA.116.003606
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Baseline Clinical Characteristics According to Pulmonary Hypertension and RV Dysfunction Category
| Characteristic | Normal PASP/Normal Right Ventricle (n=509) | Elevated PASP/Normal Right Ventricle (n=373) | Normal PASP/RV Dysfunction (n=64) | Elevated PASP/RV Dysfunction (n=98) |
|
|---|---|---|---|---|---|
| Age, y | 60±12 | 69±11 | 61±12 | 69±12 | <0.0001 |
| Female sex | 117 (23) | 138 (37) | 15 (23) | 31 (32) | <0.0001 |
| History of hypertension | 243 (48) | 236 (63) | 33 (51) | 52 (53) | <0.0001 |
| Diabetes mellitus | 122 (24) | 122 (33) | 13 (20) | 38 (39) | 0.001 |
| Current smoker | 101 (20) | 61 (16) | 12 (19) | 19 (19) | 0.61 |
| Previous infarction | 96 (19) | 95 (25) | 8 (13) | 21 (21) | 0.03 |
| Creatinine, mg/dL | 1.0±0.5 | 1.2±0.7 | 1.1±0.4 | 1.3±0.8 | <0.0001 |
| eGFR, mL·min−1·1.73 m−2 | 91±38 | 72±31 | 80±29 | 66±26 | <0.0001 |
| ST‐segment elevation myocardial infarction | 431 (85) | 298 (80) | 61 (95) | 80 (81) | 0.01 |
| Coronary revascularization | 289 (57) | 163 (44) | 27 (42) | 36 (37) | <0.0001 |
| Killip class >I | 59 (12) | 150 (40) | 8 (13) | 45 (46) | <0.0001 |
| LV wall motion score index | 1.6±0.4 | 1.8±0.4 | 1.7±0.4 | 1.9±0.4 | <0.0001 |
| LVEF <45% | 144 (28) | 223 (60) | 26 (41) | 70 (71) | <0.0001 |
| PASP, mm Hg | 29±4 | 46±9 | 28±5 | 48±11 | <0.0001 |
| RV infarction | 33 (6) | 10 (3) | 50 (78) | 47 (48) | <0.0001 |
| Medications | |||||
| Beta blockers | 453 (89) | 323 (87) | 55 (86) | 79 (81) | 0.14 |
| ACEIs/ARBs | 441 (87) | 320 (86) | 56 (88) | 70 (71) | 0.001 |
| Antiplatelet agents | 504 (99) | 360 (97) | 63 (98) | 91 (93) | 0.002 |
| Statins | 444 (83) | 275 (74) | 52 (81) | 66 (67) | <0.0001 |
Values are expressed as number (%) of patients or mean value±SD. ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate; LV, left ventricular; LVEF, left ventricular ejection fraction; PASP, pulmonary artery systolic pressure; RV, right ventricular.
Figure 1Comparison of regional left ventricular wall motion score (16‐segment model)10 in patients with RV dysfunction in the setting of acute RV infraction and RV dysfunction from other causes. Each segment received a score of 1–5, and the bars represent the mean±SE of the score for each segment. *P<0.01; † P<0.001; ‡ P<0.0001. RV indicates right ventricular.
Figure 2Landmark analyses (Kaplan–Meier estimates) of the cumulative probability of mortality during the first 30 days (left side panel) and beyond 30 days to 8 years (right side panel) for each of the 4 study groups. PH indicates pulmonary hypertension; RV, right ventricular.
Unadjusted and Adjusted Cox Proportional Hazards Model for 30‐Day All‐Cause Mortality
| Characteristic | Unadjusted | Adjusted | ||
|---|---|---|---|---|
| HR (95% CI) |
| HR (95% CI) |
| |
| Model 1: entry to 30 days | ||||
| RV function and PH category | ||||
| Normal right ventricle, no PH | 1.0 (Referent) | — | 1.0 (Referent) | — |
| Normal right ventricle, PH | 4.84 (2.24–10.47) | <0.0001 | 1.43 (0.64–3.22) | 0.39 |
| RV dysfunction, no PH | 8.23 (3.09–21.92) | <0.0001 | 5.56 (2.05–15.09) | <0.0001 |
| RV dysfunction, PH | 9.26 (3.93–21.83) | <0.0001 | 1.44 (0.55–3.77) | 0.46 |
| Age (per 10‐year increase) | 2.28 (1.79–2.88) | <0.0001 | 1.88 (1.45–2.42) | <0.0001 |
| Diabetes mellitus | 1.91 (1.17–3.11) | 0.01 | 1.68 (1.00–2.80) | 0.048 |
| Primary PCI | 0.34 (0.18–0.62) | <0.0001 | 0.37 (0.19–0.69) | 0.002 |
| Killip class >I | 2.48 (2.04–3.01) | <0.0001 | 2.26 (1.77–2.88) | <0.0001 |
| LVEF <45% | 4.09 (2.33–7.18) | <0.0001 | 2.08 (1.13–3.81) | 0.018 |
| Model 2: 31 days to 8 years | ||||
| RV function and PH category | ||||
| Normal right ventricle, no PH | 1.0 (Referent) | — | 1.0 (Referent) | — |
| Normal right ventricle, PH | 3.24 (2.37–4.43) | <0.0001 | 1.89 (1.37–2.60) | <0.0001 |
| RV dysfunction, no PH | 1.32 (0.63–2.77) | 0.46 | 1.44 (0.68–3.04) | 0.34 |
| RV dysfunction, PH | 4.91 (3.27–7.37) | <0.0001 | 2.52 (1.64–3.87) | <0.0001 |
| Age (per 10‐year increase) | 2.03 (1.81–2.28) | <0.0001 | 1.73 (1.52–1.96) | <0.0001 |
| Diabetes mellitus | 2.00 (1.55–2.60) | <0.0001 | 1.68 (1.29–2.19) | <0.0001 |
| eGFR <60 mL·min−1·1.73 m−2 | 2.79 (2.16–3.61) | <0.0001 | 1.36 (1.03–1.79) | 0.03 |
| Coronary revascularization | 0.35 (0.26–0.46) | <0.0001 | 0.43 (0.32–0.58) | <0.0001 |
| LVEF <45% | 2.22 (1.72–2.88) | <0.0001 | 1.61 (1.23–2.10) | <0.0001 |
eGFR indicates estimated glomerular filtration rate; HR, hazard ratio; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; PH, pulmonary hypertension; RV, right ventricular.
Figure 3Cubic spline analysis showing the change in (A) the hazard ratio for mortality and (B) the subhazard ratio for readmission for heart failure with increasing estimated PASP. PASP indicates pulmonary artery systolic pressure.
Figure 4Cumulative incidence of readmissions due to heart failure in the 4 study groups. The cumulative incidence function indicates the probability of observing a heart failure event before a given time. PH indicates pulmonary hypertension; RV, right ventricular.
Unadjusted and Adjusted Competing Risk Regression Analysis for Heart Failure
| Characteristic | Unadjusted | Adjusted | ||
|---|---|---|---|---|
| sHR (95% CI) |
| sHR (95% CI) |
| |
| RV function and PH category | ||||
| Normal right ventricle, no PH | 1.0 (Referent) | — | 1.0 (Referent) | — |
| Normal right ventricle, PH | 3.36 (2.38–4.75) | <0.0001 | 2.10 (1.44–3.06) | <0.0001 |
| RV dysfunction, no PH | 1.12 (0.47–2.67) | 0.79 | 1.03 (0.42–2.48) | 0.96 |
| RV dysfunction, PH | 4.25 (2.69–6.70) | <0.0001 | 2.32 (1.38–3.88) | 0.002 |
| Age (per 10‐year increase) | 1.55 (1.38–1.75) | <0.0001 | 1.30 (1.13–1.50) | <0.0001 |
| Previous infarction | 2.02 (1.51–2.71) | <0.0001 | 1.64 (1.20–2.222) | 0.002 |
| Diabetes mellitus | 1.73 (1.30–2.29) | <0.0001 | 1.38 (1.03–1.85) | 0.03 |
| eGFR <60 mL·min−1·1.73 m−2 | 2.31 (1.74–3.06) | <0.0001 | — | — |
| Coronary revascularization | 0.62 (0.47–0.82) | 0.001 | — | — |
| Killip class >I at admission | 2.59 (1.95–3.42) | <0.0001 | 1.43 (1.03–2.00) | 0.04 |
| LVEF <45% | 2.69 (2.00–3.60) | <0.0001 | 1.61 (1.16–2.56) | 0.005 |
eGFR indicates estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; PH, pulmonary hypertension; RV, right ventricular; sHR, hazard ratio of the subdistribution hazard function.